Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP3 in Advanced Solid Tumors
NCT04735978Phase 1Active, not recruiting
- Sponsor
- Replimune Group, Inc.
- Start
- Dec 2020
- Primary completion
- Nov 2026
- Modality
- Oncolytic Viruses
- Countries
- 5
01
Overview
Phase 1, open-label trial of RP3 in solid tumor (advanced stage), sponsored by Replimune Group, Inc. Primary endpoints: Incidence of dose limiting toxicities at 30 days, Incidence and severity of treatment emergent adverse events at 60 days and 4 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
RP3
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04735978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04735978.